Keith Kohl of Angel Publishing's Outsider Club leads with “While Wall Street keeps chasing AI chatbots and chip stocks...” and sells a Topline Trader report titled “Nvidia's Secret Partner: The Trillion-Dollar Platform Powering AI Drug Discovery.”
The pitch points to an NVIDIA-powered drug-discovery platform with 504 advanced GPUs, robotic labs running more than 2 million experiments a week, major pharmaceutical partnerships and a stock trading between $3 and $5. It says this overlooked company could sit beneath the next wave of AI medicine.
We identify the stock below as Recursion Pharmaceuticals, Inc. (RXRX), with 96/100 confidence. No deadline or countdown is supplied in the promotion details here.
Reading between the lines
The fingerprints are unusually specific: BioHive-2 uses 504 NVIDIA H100 GPUs; Recursion says its automated laboratories can run more than 2 million experiments weekly; and the named partners include Roche and Genentech, Sanofi and Bayer. The REC-4881 familial adenomatous polyposis program and the $3-to-$5 share price narrow the search further.
The same idea is also branded as “AI Doctor.” That phrase refers to the same pitch, not a second company: Keith Kohl and Angel Publishing's Topline Trader have used it to promote Recursion as an AI-driven drug-discovery business.
The stock behind Nvidia's Secret Partner
The answer is Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). The strongest clue is BioHive-2. Recursion's May 2024 investor release and 2024 Form 10-K describe 63 NVIDIA DGX H100 systems containing 504 NVIDIA H100 Tensor Core GPUs. That is a very distinctive fingerprint, not generic AI garnish.
The deal trail points to the same place. Recursion's December 2021 collaboration announcement says Roche and Genentech agreed to a $150 million upfront payment, while its 2025 Form 10-K describes up to $5.2 billion in potential Sanofi milestones and more than $20 billion in potential additional milestones across its partnerships. The company's December 2025 REC-4881 release also reported a 43% median reduction in total polyp burden after 12 weeks.
One clue is less solid than the rest. Recursion's 2024 yearbook documents a Jensen Huang appearance and the NVIDIA relationship, and Recursion later announced a GTC partner session. Those sources don't establish that Huang personally put Recursion on the GTC stage. The stock-price clue still fits: RXRX traded at about $3.74 in after-hours market data.
What survives the paperwork
The claim-by-claim checks below separate the hard matches from the promotional stretching. They compare the copy with Recursion's investor releases, collaboration announcements, JPMorgan presentation, clinical update and 2024 and 2025 Form 10-Ks, with market data used for the share-price claim.
| The promotion claims | Verdict | What we found |
|---|
| BioHive-2 runs on 504 of NVIDIA's most advanced GPUs | Checks out | Recursion's May 2024 investor release and 2024 Form 10-K say BioHive-2 uses 63 NVIDIA DGX H100 systems containing 504 NVIDIA H100 Tensor Core GPUs. |
| Jensen Huang put the company on stage at NVIDIA's GTC conference | Can't verify | Recursion's 2024 yearbook documents a Jensen Huang appearance and NVIDIA relationship, while Recursion later announced a GTC partner session; those sources do not establish that Huang personally put Recursion on the GTC stage. |
|
Claims the record contradicts
Where the pitch outran the record
“The platform can generate more than 100 million patent-eligible drug candidates a year” — Recursion's January 2026 JPMorgan presentation says more than 100 million molecules were generated using synthetically aware design and that more than 95% were AI-generated, scored and prioritized as patentable; it does not claim 100 million novel drug candidates per year.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Other pitches from the same analyst
This is the fifth Keith Kohl promotion we've identified. The earlier four were Recursion's “AI Doctor,” up 3.15% since we revealed it; IonQ's “The GENESIS MISSION Linchpin,” down 6.44%; NexGen Energy's “The Nuclear Reckoning,” up 3.79%; and Ormat Technologies' “Geothermal Energy: 3 Key Stocks,” unchanged.
Recursion is also being teased elsewhere under “AI Doctor” by Keith Kohl and Angel Publishing's Topline Trader. In other words, readers arriving through either branded hook are looking at the same underlying company.
Setting the pitch aside: is it any good?
The pitch's central claim is simple: NVIDIA-powered automation makes drug discovery dramatically more productive, big pharma partnerships validate the platform, and Recursion is the hidden AI winner before the crowd catches on.
The first half of that chain holds up. Recursion has the NVIDIA hardware, the automated experiment capacity, named pharmaceutical collaborators and a clinical result that the promotion can point to. Those aren't imaginary props. They're in the company's releases and filings.
The chain breaks when scale gets translated into certainty and value. Recursion's January 2026 JPMorgan presentation says more than 100 million molecules were generated using synthetically aware design, with more than 95% AI-generated, scored and prioritized as patentable. It does not say the company creates 100 million novel drug candidates a year. Bayer's $80 million also wasn't $80 million in cash upfront: the record separates a $30 million cash payment from a $50 million Leaps by Bayer equity investment. And more than $20 billion in partnership value means potential milestones before royalties, not money already in the bank.
On its own merits, Recursion is a genuine, high-risk biotech and AI platform with serious infrastructure, real partners and an encouraging REC-4881 readout. But the promotion's “trillion-dollar platform” framing outruns the evidence. The crucial link is still the conversion of generated molecules and collaboration milestones into successful, revenue-producing medicines. None of the headline figures proves that step.
How confident are we? 96 out of 100. We identified Recursion Pharmaceuticals, Inc. (RXRX) from the promotion's own clues and checked 10 of its claims against filings, earnings calls, ownership records, market data and public reporting. This is our analysis, not the publisher's disclosure — we have no relationship with them.
